BridgeBio Q2 FY26 net loss narrows to $152.2 million; revenue rises 120.37% to $243.7 million
BBIO•Regulatory updates
The FDA accepted Priority Review NDAs for BBP-418 with a PDUFA date of Nov. 27, 2026, and encaleret with a PDUFA date of May 8, 2027. The oral infigratinib NDA was also submitted.
Second-quarter results
BridgeBio posted Q2 revenue of $243.7 million, more than doubled from a year earlier, driven by $222.4 million in U.S. Attruby net product revenue.
Net loss attributable to common stockholders narrowed to $152.2 million, or $0.78 per share, from $181.9 million, or $0.95 per share.
Costs and cash position
Total operating costs and expenses climbed 43.3% to $350.8 million on higher SG&A and R&D spending, while other expense was $48.8 million.
Cash, cash equivalents, and marketable securities rose to $720.2 million at June 30, excluding a preferred equity financing that closed July 1.
